School of Medicine
Showing 1-3 of 3 Results
Associate Professor of Radiation Oncology (Radiation Therapy)
BioDr. Anusha Kalbasi is Associate Professor of Radiation Oncology at the Stanford University School of Medicine. He is a member of the Stanford Cancer Institute, the Immunology and Cancer Biology programs, and the Parker Institute for Cancer Immunotherapy. As a physician-scientist, Dr. Kalbasi leads both clinical trials and laboratory research at the intersection of cancer and immunology. He is an expert in immunotherapy, radiation therapy and the treatment of patients with sarcoma, and is a board-certified radiation oncologist.
Dr. Kalbasi received his B.S. in biochemistry from UCLA and his M.D. from the David Geffen School of Medicine at UCLA, and completed pre-doctoral research training at the NCI Surgery Branch engineering apoptosis-resistant T cells for immunotherapy. He completed his research-track clinical training in radiation oncology at the University of Pennsylvania, with post-doctoral work where he studied chemokines, myeloid trafficking and the tumor-intrinsic immune response to radiation. As a post-doc at UCLA he described how pattern recognition receptor signaling can uncouple interferon signaling and antigen presentation for T cell immunotherapy. Later as a junior faculty, he described synthetic IL9R signaling as an approach to overcome T cell intrinsic limitations to cell-based therapy. In conjunction with laboratory work, Dr. Kalbasi has led early phase clinical trials, including trials investigating novel approaches to radiation therapy, neoadjuvant immunotherapy for sarcoma and first-in-human T cell therapy.
Associate Professor of Radiation Oncology, Emerita
Current Research and Scholarly InterestsOur interests include 1) study of the effect of radiation on regulatory cell subpopulations and co-stimulatory molecules, 2) use of radiation as an immune modulator for optimization of transplant regimens, 3) the role of radiation in tumor vaccine strategies, 4) study of new radiosensitizers and radioprotectors, and 5) discovery of new targeted therapies for the treatment of solid tumors.